#antigen-escape — top 20, last 7d
| 25 | ℹ |
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
(linkinghub.elsevier.com)
|
The Lancet 2026-11-17 | #car-t #myeloma #clinical trial #immunotherapy #antigen-escape |